CStone Pharma-B's stock fell sharply by 5.90% during intraday trading, continuing a negative trend for the pharmaceutical company.

The decline is primarily attributed to investor concerns over significant share dilution following the company's recent large-scale share placement. The placement was completed at a price notably below the prevailing market rate, raising immediate dilution worries and prompting sustained selling pressure from the market.

This selling pressure has extended over consecutive sessions as the market reacts to the expanded share base and its impact on per-share metrics.